Evidence map›Paper›PMID 40871708›Full record

Trial reportNutrients2025

Effects of Oral Anthocyanin Supplementation on In Vitro Neurogenesis, Hippocampus-Dependent Cognition, and Blood-Based Dementia Biomarkers: Results from a 24-Week Randomized Controlled Trial in Older Adults At Risk for Dementia (ACID).

Chiara de Lucia, Diego Alejandro Tovar-Rios, Khadija Khalifa, Silje Meihack Kvernberg, Ilaria Pola, Anne Katrine Bergland, Jodi Maple-Grødem, Richard Siow, Nicholas Ashton, Clive Ballard and 2 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03419039 (A Randomized, 24-week Parallel-group Placebo-controlled Multicenter), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03419039 naunknown statusnot on this map

A Randomized, 24-week Parallel-group Placebo-controlled Multicenter (Phase 2) Study of Anthocyanins in People at Risk for Dementia

TypeinterventionalSponsorHelse Stavanger HFRan2018 to 2021Enrolled212ConditionsDementia, Inflammation, Mild Cognitive Impairment, Coronary Artery DiseaseArmsAnthocyanins, Placebo
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Chiara de LuciaCentre for Age-Related Medicine (SESAM), Stavanger University Hospital, Armauer Hansens vei 30, 4011 Stavanger, Norway.ORCID 0000-0002-7541-2814
Diego Alejandro Tovar-RiosCentre for Age-Related Medicine (SESAM), Stavanger University Hospital, Armauer Hansens vei 30, 4011 Stavanger, Norway.ORCID 0000-0003-3490-9899
Khadija KhalifaCentre for Age-Related Medicine (SESAM), Stavanger University Hospital, Armauer Hansens vei 30, 4011 Stavanger, Norway.
Silje Meihack KvernbergCentre for Age-Related Medicine (SESAM), Stavanger University Hospital, Armauer Hansens vei 30, 4011 Stavanger, Norway.
Ilaria PolaDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Wallinsgatan 6, 431 39 Mölndal, Sweden.
Anne Katrine BerglandCentre for Age-Related Medicine (SESAM), Stavanger University Hospital, Armauer Hansens vei 30, 4011 Stavanger, Norway.ORCID 0009-0009-7299-3383
Jodi Maple-GrødemThe Centre for Movement Disorders, Stavanger University Hospital, Armauer Hansens vei 30, 4011 Stavanger, Norway.
Richard SiowSchool of Cardiovascular and Metabolic Medicine and Sciences, King's BHF Centre of Research Excellence, Faculty of Life Sciences & Medicine, King's College London, 50 Stamford Street, London SE1 9NH, UK.ORCID 0000-0003-4603-9763
Nicholas AshtonDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Wallinsgatan 6, 431 39 Mölndal, Sweden.
Clive BallardDepartment of Health and Community Sciences, Faculty of Life Sciences, University of Exeter, Heavitree Road, Exeter EX1 12LU, UK.
Sandrine ThuretDepartment of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, 125 Coldharbour Lane, London SE5 9NU, UK.ORCID 0000-0003-1260-8083
Dag AarslandCentre for Age-Related Medicine (SESAM), Stavanger University Hospital, Armauer Hansens vei 30, 4011 Stavanger, Norway.

Funding

Nasjonalforeningen for Folkehelsen 7330Western Norway Regional Health Authority 30791
6 · The paper itself

Abstract

backgroundIdentifying compounds with neuroprotective properties that target the neurogenic process will have a considerable impact on dementia prevention.

methodsThis is a secondary analysis of a 24-week randomised, double-blind, placebo-controlled anthocyanin supplementation trial in 181 participants. Using blood-derived serum collected during this trial, we treated hippocampal progenitor cells and analysed the ensuing cellular changes in the context of the participant's clinical and blood-based biomarker data.

resultsWe show that anthocyanin supplementation impacts hippocampal progenitor cells and that this can impact hippocampal-dependent cognition. We also show for the first time that blood-based dementia biomarkers correlate with human in vitro neurogenesis markers.

conclusionsOur data demonstrates moderator effects of BMI and ApoE4 carrier status and supports the need for more individualised trials. Further studies are warranted to explore the mechanism of action of anthocyanins and the use of blood-based biomarkers for clinical trial enrichment, trial individualization, and therapy development.

trial registrationNCT03419039; date first registered: 15/01/2018.

Indexed as

AnthocyaninsCognitionDementiaDietary SupplementsHippocampusNeurogenesisAdministration, OralAgedAged, 80 and overApolipoprotein E4BiomarkersDouble-Blind MethodFemaleHumansMaleAnthocyaninsApolipoprotein E4Biomarkersanthocyaninsblood-based biomarkerscognitionhippocampal progenitor cellsneurogenesis

Identifiers

PMID40871708
PMCPMC12389521

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.